Methods for characterizing viral genomes using base modifications
By using modified base and long read sequencing technology in AAV particle samples and combined with nanopore sequencing, the problem of specific analysis of AAV single-strand DNA strands was solved, and the quality control and analysis resolution of viral gene therapy products were improved.
Patent Information
- Application Number
- CN202380033294.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-17
- Filing Date
- 2023-03-16
- Publication Date
- 2024-12-03
AI Technical Summary
Existing methods are difficult to effectively analyze and characterize single-strand DNA strand specificity of adeno-associated virus (AAV) genomes, and cannot provide in-depth analysis of single-stranded AAV genomes, affecting product testing and quality control of viral vectors.
The combination of modified bases (such as 5-methylcytosine) and long-read sequencing methods is used to synthesize synthetic DNA strands that are complementary to the natural DNA strands to produce double-stranded DNA products, and the nanopore sequencer is used to detect the Modify bases, distinguish and analyze the specificity of natural DNA strands and synthetic DNA strands.
String specific identification and quantitative analysis of single-strand DNA genome in AAV particle samples was achieved, improving the resolution of viral constructs and the accuracy of quality control of gene therapy products.
Smart Images

Figure CN119072547A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to methods for characterizing viral genomes and packaging (eg, AAV genomes) using modified bases. Background Art
[0002] Adeno-associated virus (AAV) is a non-enveloped, single-stranded DNA virus that has emerged as an attractive class of therapeutic agents for delivering genetic material to host cells for gene therapy due to its ability to transduce a variety of cargoes and tissues in vivo, low risk of immunotoxicity, and mild innate and adaptive immune responses. Recombinant AAV technology relies on proper genome packaging, which can be in either a sense or antisense conformation. Standard methods for assessing the content of DNA packaged into AAV particles are currently unknown.
[0003] Existing methods can characterize structural abnormalities of AAV packaging in self-complementary AAV variants; however, they cannot provide in-depth analysis of single-stranded AAV genomes to explain the strand specificity of single-stranded AAV genomes. The complex nature of viral vectors such as AAV requires advanced methods for product testing and characterization. Therefore, methods are needed to determine the specificity of the single-stranded DNA of viral particles. Summary of the invention
[0004] The present disclosure relates to a method for single-stranded DNA strand differentiation, which uses a combination of the incorporation of modified bases and long-read sequencing methods to retain strand-specific information in a sample of viral particles (e.g., AAV). In an exemplary embodiment, modified bases such as 5-methylcytosine (5mC) are used to label single-stranded DNA that can be detected by a nanopore sequencer platform, thereby allowing identification of the specificity of the sequenced strand. Selective labeling of single DNA strands of viral genomes and their subsequent analysis can be used in a unique way to perform viral gene therapy quality control in a quantitative manner at the molecular level, and additionally improve the resolution of the analysis of single-stranded viral constructs.
[0005] In one aspect, the present disclosure provides a method for determining the chain specificity of a sample of viral particles containing a single-stranded DNA genome, the method comprising: (a) synthesizing a synthetic DNA chain complementary to the natural DNA chain of the sample of viral particles to produce a double-stranded DNA product, wherein the synthetic DNA chain is synthesized by incorporating a modified base; (b) purifying the synthesized double-stranded DNA product; (c) sequencing the purified double-stranded DNA product on a sequencer, wherein the sequencer identifies the nucleotide sequence in one sequenced chain of the double-stranded DNA product; and (d) determining the specificity of the natural DNA chain by identifying the specificity of the sequenced chain, and detecting whether the sequenced chain contains the modified base, wherein the presence of the modified base indicates that the sequenced chain is a synthetic DNA chain of the double-stranded DNA product.
[0006] In some embodiments, the viral particle sample comprises adeno-associated virus (AAV) particles. In some cases, the AAV particles have serotype AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV-DJ, AAV-DJ / 8, AAV-Rh10, AAV-retro, AAV-PHP.B, AAV8-PHP.eB, or AAV-PHP.S.
[0007] In some embodiments, the modified base includes 5-methylcytosine, 5-hydroxymethylcytosine, or N6-methyldeoxyadenosine. In some cases, the modified base is 5-methylcytosine.
[0008] In some embodiments, incorporation of the modified base causes the synthetic DNA strand to be methylated.
[0009] In some embodiments, the double-stranded DNA product is purified using magnetic beads.
[0010] In some embodiments, the sequencer is a nanopore sequencer.
[0011] In some embodiments, a nanopore sequencer allows entry of either the native DNA strand of a purified double-stranded DNA product or a selectively labeled synthetic DNA strand for sequencing.
[0012] In some embodiments, the native DNA strand or the selectively labeled synthetic DNA strand is sequenced using a long-read sequencing method.
[0013] In some embodiments, the modified bases of the synthetic DNA strands are detected by changing the flow of current flowing through the nanopore sequencer. In some cases, the detection of the modified bases distinguishes the synthetic DNA strands entering the nanopore sequencer from the natural DNA strands.
[0014] In some embodiments, the method further comprises identifying the percentage of packaged sense and antisense strands in the sample of viral particles based on the detection of modified bases of the synthesized DNA strands.
[0015] In one aspect, the present disclosure provides a method for distinguishing natural DNA chains from synthetic DNA chains in a sample of adeno-associated virus (AAV) particles containing a single-stranded DNA genome, the method comprising: (a) synthesizing the synthetic DNA chain complementary to the natural DNA chain to produce a double-stranded DNA product, the synthetic DNA chain comprising a modified base that selectively labels the synthetic DNA chain; (b) purifying the double-stranded DNA product; (c) sequencing the purified double-stranded DNA product on a nanopore sequencer; and (d) determining the specificity of the natural DNA chain by identifying the specificity of the sequenced chain, and detecting whether the sequenced chain contains the modified base of the synthetic DNA chain by detecting changes in the flow of current flowing through the nanopore sequencer during nanopore sequencing, wherein the presence of the modified base indicates that the sequenced chain is a synthetic DNA chain of the double-stranded DNA product.
[0016] In some embodiments, the modified base includes 5-methylcytosine, 5-hydroxymethylcytosine, or N6-methyldeoxyadenosine. In some cases, the modified base is 5-methylcytosine.
[0017] In some embodiments, the selectable labeling causes the synthetic DNA strand to be methylated.
[0018] In some embodiments, the native DNA strand or the selectively labeled synthetic DNA strand is sequenced using a long-read sequencing method.
[0019] In some embodiments, the double-stranded DNA product is purified using magnetic beads.
[0020] In some embodiments, the AAV particles are of serotype AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV-DJ, AAV-DJ / 8, AAV-Rh10, AAV-retro, AAV-PHP.B, AAV8-PHP.eB, or AAV-PHP.S.
[0021] In some embodiments, the method further comprises determining the orientation of the sequenced strand based on the detection of the modified bases of the synthesized DNA strand.
[0022] In some embodiments, the method further comprises identifying the proportion of each of the sense strand and the antisense strand packaged in the sample of adeno-associated virus (AAV) particles based on the determination of the orientation of the sequenced strand.
[0023] In some embodiments, the viral particle comprises an exogenous gene in a single-stranded DNA genome. In some cases, the exogenous gene is a therapeutic gene.
[0024] In some embodiments, the method further comprises determining the complete sequence of the sequenced strand.
[0025] In some embodiments, the method further comprises identifying a complementary nucleotide sequence corresponding to the complete sequence if the sequenced strand is a synthetic DNA strand of a double-stranded DNA product.
[0026] In any of the embodiments discussed above or herein, sequencing of nucleic acids identifies about 100 to about 5000 nucleotides in the sequenced strand. In some cases, sequencing identifies 100 to 1000 nucleotides in the sequenced strand. In some cases, sequencing identifies 100 to 500 nucleotides in the sequenced strand.
[0027] In any of the various embodiments discussed above or herein, sequencing of the nucleic acid is performed without fragmenting the sequenced strand.
[0028] In various embodiments, any features or components of the embodiments discussed above or herein can be combined, and such combinations are included in the scope of the present disclosure. Any specified value discussed above or herein can be combined with another related value discussed above or herein to list a range, and the value represents the upper and lower limits of the range, and such ranges are included in the scope of the present disclosure.
[0029] Other embodiments will become apparent upon reading the ensuing detailed description. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figure 1 Shown is an AAV capsid with a single-stranded DNA genome comprising a therapeutic gene or gene of interest (GOI).
[0031] Figure 2 An overview of an exemplary method for determining the chain specificity of AAV particles according to embodiments of the present disclosure is shown.
[0032] Figure 3 A process for second strand synthesis according to an embodiment of the present disclosure is shown, showing the incorporation of modified bases and selective labeling of the synthesized second strand. "CH3" refers to methylation.
[0033] Figure 4 Purification of the second strand synthesis product using magnetic beads is shown.
[0034] Figure 5Shown is the sequencing of the second strand synthesis product on a nanopore sequencer, and the determination of the sequence of the sequenced strand based on changes in the flow of current through the nanopore sequencer.
[0035] Fig. 6A and 6B The chemical structures of the unmodified base cytosine and the modified base 5-methylcytosine are shown separately.
[0036] Figure 6C Shown is the sequencing of a selectively labeled DNA strand versus an unlabeled DNA strand by a nanopore sequencer, where a change in current flow is detected indicating the presence of the modified base 5-methylcytosine. "Me" or "CH3" refers to methylation. DETAILED DESCRIPTION
[0037] Before describing the present invention, it should be understood that the present invention is not limited to the specific methods and experimental conditions described, because such methods and conditions can vary. It should also be understood that the terminology used herein is only used for the purpose of describing specific embodiments, and is not intended to be limiting, because the scope of the present invention will be limited only by the appended claims.
[0038] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. As used herein, the term "about" when used in reference to a specific recited numerical value means that the value may vary by no more than 1% from the recited value. For example, as used herein, the expression "about 100" includes 99 and 101 and all values therebetween (e.g., 99.1, 99.2, 99.3, 99.4, etc.).
[0039] As used herein, the terms "include," "includes," and "including" are intended to be non-limiting, and may be understood to mean "comprise," "comprises," and "comprising," respectively.
[0040] Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All patents, applications and non-patent publications mentioned in this specification are incorporated herein by reference in their entirety.
[0041] Selected Abbreviations
[0042] AAV: adeno-associated virus
[0043] ssDNA: single-stranded DNA
[0044] dsDNA: double-stranded DNA
[0045] GOI: gene of interest
[0046] PCR: polymerase chain reaction
[0047] 5mC: 5-methylcytosine
[0048] dNTP: deoxyribonucleotide triphosphate
[0049] dATP: deoxyadenosine triphosphate
[0050] dGTP: deoxyguanosine triphosphate
[0051] dTTP: deoxythymidine triphosphate
[0052] dCTP: deoxycytidine triphosphate
[0053] NFW: Nuclease-free water
[0054] definition
[0055] "Adeno-associated virus" or "AAV" is a non-pathogenic parvovirus with single-stranded DNA, a genome of approximately 4.7 kb, no envelope, and an icosahedral conformation. AAV was first discovered in 1965 as a contaminant of adenovirus preparations. AAV belongs to the genus Dependovirus and the family Parvoviridae and requires the helper functions of herpesvirus or adenovirus to replicate. In the absence of a helper virus, AAV can establish latency by integrating into the 19q13.4 position of human chromosome 19. The AAV genome consists of two open reading frames (ORFs), one for each of the two AAV genes Rep and Cap. The AAV DNA ends have 145 bp inverted terminal repeats (ITRs), and the 125 terminal bases are palindromic, producing a characteristic T-shaped hairpin structure.
[0056] As used herein, the term "sample" refers to a mixture of viral particles (e.g., AAV particles) comprising at least one viral capsid component encapsulating a single-stranded DNA genome, which viral capsid component is manipulated according to the methods of the invention (including, for example, selective labeling and sequencing).
[0057] As used herein, the term "nucleic acid" refers to a polymeric form of nucleotides of any length, i.e., ribonucleotides or deoxyribonucleotides. Thus, the term includes, but is not limited to, single-stranded, double-stranded or multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids, or polymers containing purine and pyrimidine bases or other natural, chemically or biochemically modified, non-natural or derivatized nucleotide bases. The backbone of the nucleic acid may contain sugar and phosphate groups (as may be commonly present in RNA or DNA), or modified or substituted sugar or phosphate groups.
[0058] A "recombinant viral particle" refers to a viral particle that contains one or more exogenous genes or heterologous sequences (eg, nucleic acid sequences of non-viral origin), which may be flanked by at least one viral nucleotide sequence.
[0059] "Recombinant AAV particles" refer to adeno-associated virus particles comprising one or more heterologous sequences (e.g., nucleic acid sequences not derived from AAV), which may be flanked by at least one (e.g., two) AAV inverted terminal repeats (ITRs). Such rAAV particles can replicate and package when present in host cells that have been infected with a suitable helper virus (or express a suitable helper function) and express AAV rep and cap gene products (i.e., AAV Rep and Cap proteins).
[0060] "Viral particle" refers to a viral particle composed of at least one viral capsid protein and the encapsidated viral genome.
[0061] "Heterologous" or "exogenous" means derived from an entity that is genotypically different from the rest of the entity to which it is compared or introduced or incorporated. For example, a nucleic acid introduced into a different cell type by genetic engineering techniques is a heterologous nucleic acid (and can encode a heterologous polypeptide when expressed). Similarly, a cellular sequence (e.g., a gene or portion thereof) incorporated into a viral particle is a heterologous or exogenous nucleotide sequence with respect to the viral particle.
[0062] The term "therapeutic gene" refers to a genetically modified gene that produces a therapeutic effect (eg, by encoding a target protein) or treats a disease by repairing or reconstructing defective genetic material.
[0063] "Inverted terminal repeat" or "ITR" sequences are relatively short sequences present at the ends of the viral genome in opposite orientations. "AAV inverted terminal repeat (ITR)" sequences are sequences of approximately 145 nucleotides present at both ends of the single-stranded AAV genome.
[0064] As used herein, the term "isolated" refers to a biological component (such as a nucleic acid, peptide, protein, lipid, viral particle, or metabolite) that has been substantially separated from, produced from, or purified from other biological components in the cells of an organism, wherein the component occurs naturally in the cells of the organism or is transgenically expressed in the cells of the organism.
[0065] As used herein, "vector" refers to a recombinant plasmid or virus containing a nucleic acid to be delivered to a host cell in vitro or in vivo. The term "corresponding to" is a relative term, indicating similarity in position, purpose or structure.
[0066] The term "read" in relation to sequencing refers to the nucleic acid sequence of a nucleotide cluster obtained after the sequencing process is completed, which is ultimately the sequence of a segment in the complete nucleic acid sequence. A "read" is a base call value of a nucleotide string derived from the original signal.
[0067] The term "long read sequencing" refers to a DNA sequencing technology that can determine the nucleotide sequence of long stretches of DNA from about 100 base pairs to about 1,000,000 base pairs or more (the upper limit may depend only on the genome being sequenced) at one time, thereby eliminating the need for fragmentation and amplification of DNA that is typically required in other DNA sequencing technologies. In one example, the AAV genome (approximately 5000 base pairs) can be sequenced in its entirety without any fragmentation.
[0068] As used herein, "amplification" refers to the production of multiple copies of a segment of DNA or RNA. Amplification is typically initiated by a polymerase chain reaction.
[0069] As used herein, "PCR" refers to polymerase chain reaction, a molecular biology technique used to amplify a single copy of a segment of DNA or RNA, thereby producing thousands to millions of copies of a specific DNA or RNA sequence. PCR is often used to amplify the number of copies of a DNA or RNA segment for cloning or for other analytical procedures.
[0070] The term "nanopore sequencing" refers to the sequencing of nucleic acid molecules by the alteration of the flow of electric current per base as the nucleic acid molecule passes through a nanopore.
[0071] The term "strand specificity" refers to the positive strand or sense strand and the negative strand or antisense strand of the viral genome. The positive strand or sense strand is the coding strand of the gene, while the negative strand or antisense strand is the non-coding strand of the gene.
[0072] General Description
[0073] The present disclosure provides a method for the synthesis and labeling of synthetic DNA chains, which is performed by incorporating modified bases, and sequencing the labeled synthetic DNA chains can provide rapid identification of the chain specificity of the ssDNA genome of a sample of viral particles (e.g., AAV particles). The method of the present invention utilizes a long read sequencing-based method performed on a nanopore sequencer to identify and quantify the chain specificity of the viral genome. Quantitative characterization of the ratio of each of the sense and antisense chains packaged in a sample of AAV particles is necessary to ensure product quality and consistency, thereby greatly simplifying the quality control process.
[0074] Strand-specific method for identification and quantification of viral single-stranded DNA genomes
[0075] Aspects of the present disclosure relate to methods for identifying and quantifying strand-specificity of ssDNA genomes in samples of viral particles (eg, recombinant AAV particles) using incorporation of modified bases in combination with long-read sequencing methods.
[0076] In some cases, the method includes: (a) synthesizing a synthetic DNA chain complementary to the natural DNA chain of the sample of viral particles to produce a double-stranded DNA product, wherein the synthetic DNA chain is synthesized by incorporating a modified base; (b) purifying the synthesized double-stranded DNA product; (c) sequencing the purified double-stranded DNA product on a sequencer, wherein the sequencer identifies the nucleotide sequence in one sequenced chain of the double-stranded DNA product; and (d) determining the specificity of the natural DNA chain by identifying the specificity of the sequenced chain, and detecting whether the sequenced chain contains the modified base, wherein the presence of the modified base indicates that the sequenced chain is a synthetic DNA chain of the double-stranded DNA product.
[0077] Figure 1 An adeno-associated virus particle 100 and its single-stranded DNA genome are shown. Figure 1 In the example shown, the ssDNA genome of AAV is highly symmetrical and has palindromic elements. In addition, the ssDNA genome of AAV contains approximately 70% GC content and inverted terminal repeats. In some examples, for example, the single-stranded DNA genome of recombinant AAV can contain a therapeutic gene or a gene of interest (GOI) for gene therapy purposes.
[0078] In the methods disclosed herein, a method 200 for determining the chain specificity of an AAV particle is performed by Figure 2 The schematic diagram shown is used as an example. Figure 2In the exemplary method shown, ssDNA genome 204 is extracted or isolated from a sample of AAV particles 202. In one example, the isolated ssDNA genome 204 can be prepared by lysing the nucleocapsid and releasing the viral ssDNA using phenol-chloroform extraction, while in other examples, the isolated ssDNA genome 204 can be prepared by alkaline lysis extraction. The isolated ssDNA genome 204 is then subjected to synthesis of a synthetic DNA chain or second strand synthesis, and modified bases are incorporated to produce selectively labeled double-stranded DNA 206. The labeled double-stranded DNA 206 is purified from the second strand synthesis reaction. In one example, the purification of the double-stranded DNA 206 can be performed using magnetic beads. Subsequently, the purified double-stranded DNA 206 is sequenced on a nanopore sequencer 208, wherein the sequencer identifies the nucleotide sequence in one sequenced strand of the double-stranded DNA product. More details about second strand synthesis, purification of labeled double-stranded DNA, and nanopore sequencing are shown in subsequent figures.
[0079] In various embodiments of the methods discussed herein, an example of second strand synthesis 300 is Figure 3 As shown. The natural ssDNA chain 302 (can be similar to Figure 2 The ssDNA genome 204) can be used as a template for synthesizing a synthetic DNA chain complementary to the natural ssDNA chain 302. In the presence of nucleotide bases and modified random hexamers, the second chain synthesis is catalyzed by the Klenow fragment. The second chain synthesis reaction uses modified bases to selectively label the synthetic DNA chain. In multiple embodiments of the method, the modified base includes 5-methylcytosine, 5-hydroxymethylcytosine, or N6-methyldeoxyadenosine. In some cases, the modified base is 5-methylcytosine. The second chain synthesis promotes the formation of a double-stranded DNA product 310 in which the synthetic DNA chain is methylated (CH3), such as Figure 3 shown.
[0080] The labeled double-stranded DNA product 310 is then purified from the second strand synthesis reaction. Figure 4 As shown in the figure, the purification of the labeled double-stranded DNA product 310 using magnetic beads 410 is shown. The labeled dsDNA product 310 is conjugated to the magnetic beads 410, and the labeled dsDNA product is separated from the second strand synthesis reactant using a magnet. Then, the labeled dsDNA product 310 is washed and eluted from the magnetic beads 410.
[0081] In embodiments of the methods discussed herein, the purified double-stranded DNA product is ultimately submitted for sequencing. Figure 5As shown, the sequencing 500 of the product of the second strand synthesis is performed on a nanopore sequencer 502 using a long read technology that provides a single read of about 100 base pairs to 1000 kb or longer. As shown, the nanopore 504 of the nanopore sequencer 502 identifies the sequence of nucleotides in one sequenced strand of the double-stranded DNA product. The identification of the nucleotide sequence in the sequenced strand is based on the ability of each nucleotide base to uniquely change the flow of current when passing through the nanopore 504. Figure 5 Describe a curve graph 506, which shows each base that changes the current flow over time. In an example, the double-stranded DNA product does not need to be fragmented for sequencing, thereby allowing the length of the read segment to be as long as the entire virus (e.g., AAV) genome. In multiple embodiments, the number of nucleotides sequenced without fragmentation is about 100 to about 1,000,000. In some cases, the number of nucleotides sequenced without fragmentation is about 100 to about 10,000. In some cases, the number of nucleotides sequenced without fragmentation is about 100 to about 9000, to about 8000, to about 7000, to about 6000 or to about 5000 (e.g., nucleotides in the sequenced chain).
[0082] The obtained sequencing data is analyzed to determine whether the modified base is present in the sequenced strand of the dsDNA product. The chemical structures of the unmodified nucleobase cytosine and the modified nucleobase 5-methylcytosine with an additional methyl group (CH3) are as follows: Fig. 6A and 6B Both modified and unmodified nucleobases alter the flow of current through the nanopore in different ways. Figure 6C As shown, the detection of modified bases during sequencing indicates that the sequenced strand is a synthetic DNA strand of a double-stranded DNA product because the synthetic DNA strand is modified (e.g., methylated). However, the failure to detect modified bases during sequencing indicates that the sequenced strand is a natural DNA strand of a double-stranded DNA product because the natural DNA strand is non-methylated. Figure 6C A graph 610 is depicted showing changes in the flow of current corresponding to methylated (modified) and non-methylated (unmodified) strands over time.
[0083] The methods discussed herein include determining the specificity of the natural DNA strand by identifying the specificity of the sequenced strand. If the sequenced strand is a synthetic DNA strand of a double-stranded DNA product, the specificity of the natural DNA strand of the AAV genome can be determined by identifying the complementary nucleotide sequence corresponding to the complete sequence. In addition, the ratio of each of the sense strand and the antisense strand packaged in a sample of AAV particles can be identified based on the detection of modified bases of the synthetic DNA strand.
[0084] Virus particles
[0085] In some aspects, the viral particles are AAV particles, and the disclosed methods can be used to determine the specificity of the ssDNA genome and identify the proportion of each of the sense strand and the antisense strand packaged in a sample of AAV particles. The AAV particles can be recombinant AAV (rAAV) particles. The rAAV particles contain an AAV vector encoding a heterologous transgene or a heterologous nucleic acid molecule. In some aspects, the AAV particles contain AAV1 capsids, AAV2 capsids, AAV3 capsids, AAV4 capsids, AAV5 capsids, AAV6 capsids, AAV7 capsids, AAV8 capsids, AAVrh8 capsids, AAV9 capsids, AAV10 capsids, AAV11 capsids, AAV12 capsids, or variants thereof. In certain aspects, the AAV particles are of serotype AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV-DJ, AAV-DJ / 8, AAV-Rh10, AAV-retro, AAV-PHP.B, AAV8-PHP.eB, or AAV-PHP.S. In some embodiments, the AAV particles are of serotype AAV1 or AAV8.
[0086] Although AAV is a model viral particle of the present disclosure, it is expected that the disclosed methods can be applied to characterize a variety of viruses, such as viral families, subfamilies, and genera. The methods of the present disclosure can be used, for example, to characterize viral particles to monitor or detect the relative abundance of each of the sense strand and antisense strand packaged in such compositions during production, purification, or storage of compositions of viral particles. In an exemplary embodiment, the viral particles belong to a viral family selected from the group consisting of Parvoviridae.
[0087] In certain aspects, the viral particle belongs to a viral genus selected from the group consisting of: Ambidensovirus, Brevidensovirus, Hepandensovirus, Iteradensovirus, Penstyldensovirus, Amdoparvovirus, Aveparvovirus, Bocaparvovirus, Copiparvovirus, Dependoparvovirus, Erythroparvovirus, Protoparvovirus, and Tetraparvovirus.
[0088] In some aspects, the viral particle (e.g., AAV particle) contains a heterologous nucleic acid molecule or an exogenous gene (e.g., a therapeutic gene or a target gene). In some aspects, the heterologous nucleic acid molecule is operably linked to a promoter. Exemplary promoters include, but are not limited to, cytomegalovirus (CMV) immediate early promoter, RSV LTR, MoMLV LTR, phosphoglycerate kinase-1 (PGK) promoter, simian virus 40 (SV40) promoter, and CK6 promoter, transthyretin promoter (TTR), TK promoter, tetracycline responsive promoter (TRE), HBV promoter, hAAT promoter, LSP promoter, chimeric liver-specific promoter (LSP), E2F promoter, telomerase (hTERT) promoter; cytomegalovirus enhancer / chicken β-actin / rabbit β-globin promoter and elongation factor 1-α promoter (EF1-α) promoter. In some aspects, the promoter includes a human β-glucuronidase promoter or a cytomegalovirus enhancer connected to a chicken β-actin (CBA) promoter. The promoter can be a constitutive, inducible or repressible promoter. In some aspects, the invention provides a recombinant vector comprising a nucleic acid encoding a heterologous transgenic disclosed herein that is operably connected to a CBA promoter. In some cases, a natural promoter or a fragment thereof of the transgenic will be used. When the expression of the transgenic is required to simulate natural expression, a natural promoter can be used. When the expression of the transgenic must be regulated in time or development, or in a tissue-specific manner, or in response to a specific transcriptional stimulus, a natural promoter can be used. In another aspect, other natural expression control elements (such as enhancer elements, polyadenylation sites or Kozak consensus sequences) can also be used to simulate natural expression.
[0089] Example
[0090] The following examples are provided to provide a person of ordinary skill in the art with a complete disclosure and description of how to prepare and use the methods and compositions of the present invention, and are not intended to limit the scope of what the inventors consider to be their invention. Efforts have been made to ensure the accuracy of the numbers used (e.g., amounts, temperatures, etc.), but certain experimental errors and deviations should be considered. Unless otherwise indicated, parts are parts by weight, molecular weights are average molecular weights, temperatures are in degrees Celsius, and pressures are at or near atmospheric pressure.
[0091] Example 1: Characterization of the viral ssDNA genome of AAV particles
[0092] AAV samples of different serotypes were prepared in-house. Total nucleic acid (ssDNA genome) was extracted from AAV cultured in human hosts. Second-strand synthesis was performed on the nucleic acid extract with the incorporation of modified bases to produce labeled dsDNA products. Agencourt AMPure XP beads (Beckman Coulter) were used to purify dsDNA products from the second-strand synthesis reaction. The purified dsDNA products were sequenced on a GridION nanopore sequencer (Oxford Nanopore Technologies) and the data were analyzed using bioinformatics analysis.
[0093] Chemicals and reagents
[0094] Unless otherwise stated, all chemicals and reagents were obtained from MilliporeSigma (Burlington, MA, USA). AAV samples and nucleic acid extracts thereof were provided in-house (Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA). Agencourt AMPure XP beads were obtained from Beckman Coulter (Indianapolis, IN, USA). Sigma-Aldrich molecular grade 200 degree ethanol was obtained from MilliporeSigma. Oxford Nanopore Technology flow cell pretreatment kit and Oxford Nanopore Technology rapid sequencing kit were purchased from Oxford Nanopore Technologies (Oxford, UK). 1.5 ml DNA / RNA LoBind tubes were obtained from VWR (Atlanta, GA, USA). NEB single dNTPs and NEB modified 5mC dCTPs were purchased from Thermo Fisher Scientific (Waltham, MA, USA). Modified random hexamers were purchased from Integrated DNA Technologies (Coralville, IA, USA).
[0095] Second strand synthesis experiments
[0096] The total nucleic acid extract of AAV is subjected to the second chain synthesis reaction. A dNTP master mixture is prepared, wherein the working concentration of each of dATP, dTTP, dGTP and dCTP (5mC) is 10mM. The reaction mixture is prepared in nuclease-free water. 1 μg of total nucleic acid extract, 10mM dNTP master mixture and 60 μM modified random hexamer (primer) are added to the reaction mixture. The reaction mixture is heated to 95°C for three minutes and then gradually cooled at room temperature for 10 minutes. Subsequently, 2U / μL Klenow enzyme is added to the reaction mixture, and the reaction mixture is incubated at 30°C for 1 hour. The second chain synthesis reaction is terminated by incubating the reaction mixture at 75°C for 10 minutes.
[0097] Purification of second-strand synthesis products
[0098] The second strand synthesis reaction was placed in a 1.5 mL DNA / RNA LoBind tube and then subjected to a purification assay. The dsDNA product from the second strand synthesis reaction was purified using Agencourt AMPure XP beads (magnetic beads). The dsDNA product was first conjugated to the magnetic beads by adding the resuspended AMPure XP beads to the second strand synthesis reaction in a 1:1 ratio. The mixture of magnetic beads and the second strand synthesis reaction was incubated on a mixer set at a medium stirring speed for 5 minutes and then centrifuged briefly. The tube containing the mixture of magnetic beads and the second strand synthesis reaction was then placed on a magnetic stand for 3 minutes until the magnetic beads rested on the tube wall. The supernatant was discarded without disturbing the magnetic beads. The first ethanol wash was performed by resuspending the magnetic beads conjugated to dsDNA in 80% ethanol. The tube was then placed on a magnetic stand again for 3 minutes until the magnetic beads rested on the tube wall, and the supernatant was discarded without disturbing the magnetic beads. The magnetic beads conjugated to dsDNA were washed with 80% ethanol for a second time in a similar manner. Finally, dsDNA was eluted from the magnetic beads by suspending the magnetic beads in nuclease-free water and gently agitating or stirring for 5 minutes. The tube containing NFW and magnetic beads was briefly centrifuged and placed on a magnetic stand for 5 minutes until the beads formed a pellet against the tube wall and the aqueous solution containing the amplicons became clear. The aqueous solution (eluate) was then removed and transferred to a 0.2 mL PCR tube for storage, and the magnetic beads were discarded.
[0099] Nanopore sequencing of purified second-strand synthesis products
[0100] The purified dsDNA product is sequenced on the GridION nanopore sequencer (Oxford Nanopore Technologies, Oxford, UK). The GridION sequencer and flow cell are prepared for sequencing in the following manner: the flow cell is gently placed in a specified GridION slot. It has been verified that the number of active holes for sequencing is 1000 or more. The flow cell is pretreated using a flow cell pretreatment kit (Oxford Nanopore Technologies, Oxford, UK), and the fluid flow is checked without introducing any bubbles. After the flow cell is kept stationary for at least 15 minutes, the SpotON sample port cover is gently lifted to open the SpotON sample port. The purified dsDNA product is then prepared for sequencing to form a sequencing template library. In short, 1000ng of the purified dsDNA product is fragmented into fragments with an average size of about 800 base pairs using a rapid sequencing kit (Oxford Nanopore Technologies, Oxford, UK), the ends are repaired, and connected to the sequencing connector. The sequencing template library was mixed with the flow cell loading mixture and then the entire volume was added dropwise to the flow cell of the sequencer through the SpotON sample port, ensuring that there were no bubbles. The SpotON sample port cover was gently replaced, the flow cell pretreatment port was closed, and sequencing was started on the nanopore sequencer using a standard protocol. Sequencing was automatically terminated after 48 hours.
[0101] Data analysis
[0102] After sequencing is terminated, the FASTQ file is transferred to the AWS cloud infrastructure platform for bioinformatics analysis. The resulting sequencing data is analyzed to determine whether there are modified bases in the sequenced strands of the dsDNA product. Indicators for nanopore-based sequencing include absolute current flow at a given time, duration of a given current flow measurement, duration of current measurement indicating that the detection area does not contain a nucleobase, duration between current measurements representing specific bases, magnitude of change from baseline current measurement, and magnitude of change from previous subsequent current measurement.
[0103] Results and discussion
[0104] Using an exemplary method (such as Figure 2 The method performs second-strand synthesis of the ssDNA genome of isolated AAV particles ( Figure 3 ), magnetic bead-assisted purification of the second strand synthesis product ( Figure 4 ) and nanopore sequencing of the second-strand synthesis products at 48 hours ( Figure 5 After sequencing, the specificity of the isolated single-stranded AAV genome is determined by identifying the specificity of the sequenced strand ( Fig. 6A , 6B and 6C).
[0105] In the second strand synthesis reaction, a synthetic DNA strand complementary to the native strand of the ssDNA genome of the isolated AAV is synthesized. The modified base (5mC-dCTP) is incorporated into the second strand synthesis reactant, which causes the synthetic DNA strand to be methylated, thereby selectively labeling the synthetic DNA strand. Therefore, the reaction produces a dsDNA product with a labeled synthetic DNA strand. The labeling of the synthetic second strand can achieve a higher degree of separation between the positive sense strand and the negative antisense strand. After the second strand is synthesized, the labeled dsDNA product is purified from the second strand synthesis reactant using magnetic beads. The labeled dsDNA product is first conjugated to the magnetic beads, and then the labeled dsDNA product is eluted from the magnetic beads after the labeled dsDNA product is separated from the rest of the second strand synthesis reactant.
[0106] Nanopore sequencing of purified dsDNA products utilizes long read sequencing technology that provides single reads ranging from about 100 base pairs to 1000 kb or longer. In an embodiment, the purified double-stranded DNA product does not need to be fragmented for sequencing, allowing the entire length of the read to be as long as the viral (e.g., AAV) genome. Long reads are particularly useful for determining the location of short read mapping, which helps to assemble metagenomic samples into larger contigs and the assembly of whole genomes. The nanopore sequencer identifies the nucleotide sequence (e.g., nucleotide sequence) in one sequenced strand of the double-stranded DNA product. Figure 6C shown).
[0107] Single-molecule sequencing reactions using nanopore sensors are primarily characterized around changes in the current flowing through the nanopore itself, for example, the rate at which the current fluctuates (indicating that the "next" base in the template is in the detection zone of the pore), as well as the amplitude of the current fluctuations themselves, and all aspects of the noise measured during these fluctuations. Each base uniquely changes the current flow as the template passes through the nanopore ( Figure 5 ). In addition, modified nucleobases in the template can also be detected by changes in the current flow through the nanopore compared to unmodified nucleobases ( Figure 6C ). In addition, when a protein (e.g., a helicase or polymerase) is used to drive the template through the nanopore, the interaction of the protein with the template before it enters the pore can affect the sequence detection kinetics of a portion of the template within the detection zone of the pore. In this way, upstream modified nucleobases can affect the detection of unmodified bases within the nanopore.
[0108] The obtained sequencing data is analyzed to determine whether a modified base (5mC-dCTP) is present in the sequenced strand of the dsDNA product. The reads can be grouped according to the similarity of the motifs with the modified bases. For example, reads with a methylation / modification pattern are grouped into a first group, and reads without a methylation / modification pattern are grouped into a second group. The detection of a modified base or 5mC indicates that the sequenced strand is a synthetic DNA strand of a double-stranded DNA product, while the failure to detect a modified base or 5mC indicates that the sequenced strand is a natural DNA strand of a double-stranded DNA product (see, e.g., Fig. 6A , 6B and 6C).
[0109] If the sequenced strand is a synthetic DNA strand of a double-stranded DNA product, the specificity of the isolated single-stranded AAV genome can be determined by identifying the complementary nucleotide sequence corresponding to the complete sequence. In addition, the proportion of each of the sense strand and antisense strand packaged in a sample of AAV particles is identified based on the detection of modified bases of the synthetic DNA strand.
[0110] The scope of the present invention is not limited by the specific embodiments described herein. In fact, various modifications of the present invention, except those described herein, will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.
[0111] *******
Claims
1. A method for determining the strand specificity of a sample of viral particles containing a single-stranded DNA genome, the method comprising: include: (a) synthesizing a synthetic DNA chain complementary to a natural DNA chain of the sample of virus particles to produce a double-stranded DNA product, wherein the synthetic DNA chain is synthesized by incorporating a modified base; (b) purifying the synthesized double-stranded DNA product; (c) sequencing the purified double-stranded DNA product on a sequencer, wherein the sequencer identifies the nucleotide sequence in one sequenced strand of the double-stranded DNA product; and (d) determining the specificity of the natural DNA chain by identifying the specificity of the sequenced chain, and detecting whether the sequenced chain contains the modified base, wherein the presence of the modified base indicates that the sequenced chain is a synthetic DNA chain of the double-stranded DNA product.
2. The method of claim 1, wherein the sample of viral particles comprises adeno-associated virus (AAV) particles.
3. The method of claim 2, wherein the AAV particles are of serotype AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV-DJ, AAV-DJ / 8, AAV-Rh10, AAV-retro, AAV-PHP.B, AAV8-PHP.eB or AAV-PHP.S.
4. The method of any one of claims 1 to 3, wherein the modified base comprises 5-methylcytosine, 5-hydroxymethylcytosine or N6-methyldeoxyadenosine. The method of claim 4 , wherein the modified base is 5-methylcytosine.
6. The method of claim 4 or claim 5, wherein the incorporation of the modified base causes the synthetic DNA strand to be methylated.
7. The method of any one of claims 1 to 6, wherein the double-stranded DNA product is purified using magnetic beads.
8. The method of any one of claims 1 to 7, wherein the sequencer is a nanopore sequencer.
9. The method of claim 8, wherein the nanopore sequencer allows the natural DNA strand or the selectively labeled synthetic DNA strand of the purified double-stranded DNA product to enter for sequencing.
10. The method of any one of claims 1 to 9, wherein the natural DNA strand or the selectively labeled synthetic DNA strand is sequenced using a long read sequencing method.
11. The method of any one of claims 1 to 10, wherein the modified base of the synthesized DNA strand is detected by altering the flow of electric current through the nanopore sequencer.
12. The method of any one of claims 8 to 11, wherein detection of the modified bases distinguishes the synthetic DNA strands entering the nanopore sequencer from the natural DNA strands.
13. The method of any one of claims 1 to 12, further comprising identifying the percentage of sense and antisense strands packaged in the sample of viral particles based on the detection of the modified bases of the synthetic DNA strands.
14. A method for distinguishing natural DNA strands from synthetic DNA strands in a sample of adeno-associated virus (AAV) particles containing a single-stranded DNA genome, the method include: (a) synthesizing the synthetic DNA chain complementary to the natural DNA chain to produce a double-stranded DNA product, wherein the synthetic DNA chain comprises a modified base that selectively labels the synthetic DNA chain; (b) purifying the double-stranded DNA product; (c) sequencing the purified double-stranded DNA product on a nanopore sequencer; as well as (d) determining the specificity of the natural DNA chain by identifying the specificity of the sequenced chain, and detecting whether the sequenced chain contains the modified base of the synthetic DNA chain by detecting changes in the flow of current flowing through the nanopore sequencer during nanopore sequencing, wherein the presence of the modified base indicates that the sequenced chain is a synthetic DNA chain of the double-stranded DNA product.
15. The method of claim 14, wherein the modified base comprises 5-methylcytosine, 5-hydroxymethylcytosine or N6-methyldeoxyadenosine.
16. The method of claim 15, wherein the modified base is 5-methylcytosine.
17. A method as claimed in claim 15 or claim 16, wherein the selectable marker causes the synthetic DNA strand to be methylated.
18. The method of any one of claims 14 to 17, wherein the natural DNA strand or the selectively labeled synthetic DNA strand is sequenced using a long read sequencing method.
19. The method of any one of claims 14 to 18, wherein the double-stranded DNA product is purified using magnetic beads.
20. The method of any one of claims 14 to 19, wherein the AAV particles are of serotype AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV-DJ, AAV-DJ / 8, AAV-Rh10, AAV-retro, AAV-PHP.B, AAV8-PHP.eB, or AAV-PHP.S.
21. The method of any one of claims 14 to 20, further comprising determining the orientation of the sequenced strand based on the detection of the modified base of the synthetic DNA strand.
22. The method of claim 21, further comprising identifying a proportion of each of a sense strand and an antisense strand packaged in the sample of adeno-associated virus (AAV) particles based on the determination of the orientation of the sequenced strand.
23. The method of any one of claims 1 to 22, wherein the viral particle comprises a foreign gene in the single-stranded DNA genome.
24. The method of claim 23, wherein the exogenous gene is a therapeutic gene.
25. The method of any one of claims 1 to 24, further comprising determining the complete sequence of the sequenced strand.
26. The method of claim 25, further comprising identifying a complementary nucleotide sequence corresponding to the complete sequence when the sequenced strand is the synthetic DNA strand of the double-stranded DNA product.
27. The method of any one of claims 1 to 26, wherein the sequencing identifies about 100 to about 5000 nucleotides in the sequenced strand.
28. The method of claim 27, wherein the sequencing identifies 100 to 1000 nucleotides in the sequenced strand.
29. The method of claim 28, wherein the sequencing identifies 100 to 500 nucleotides in the sequenced strand.
30. The method of any one of claims 1 to 29, wherein the sequencing is performed without fragmenting the sequenced strand.
